Compare Enveric Biosciences Inc (ENVB) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sibanye Stillwater Ltd — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Sibanye Stillwater Ltd trades at $8.07 (market cap $5.93B). The key difference: Sibanye Stillwater Ltd is far larger — about 1114.7× Enveric Biosciences Inc's market cap, and Sibanye Stillwater Ltd pays a 3.64% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SBSW | |
|---|---|---|
Market Cap | $5.32M | $5.93B |
Sector | Health | Basic Materials |
52-Week High | $17.40 | $21.12 |
52-Week Low | $1.28 | $7.27 |
Enterprise Value | $408.82K | $7.56B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Sibanye Stillwater (SBSW) trades at $8.12, down 5.25% today, reflecting ongoing challenges despite a low P/E of 4.76 and P/S of 0.77. The stock shows bearish technical signals with key support at $8, while fundamentals reveal negative net income margins and ROE. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, yet earnings misses in recent quarters underscore persistent profitability issues.
The outlook is mixed: deep valuation discounts and analyst consensus targets near $14.25 suggest upside potential, but risks from volatile commodity prices, high debt, and inconsistent earnings warrant caution. Investors should weigh the turnaround narrative against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
